STANDARD BIOTOOLS INC. (LAB): restructuring charge — Standard BioTools to consolidate R&D to Singapore, reduce US workforce, expects $3.6M in costs

STANDARD BIOTOOLS INC.

Consolidates South San Francisco R&D into Singapore facility to co-locate with manufacturing.
Reduction-in-force of certain US R&D employees, including management team members.
Estimated total expenses of ~$3.6M, including ~$0.9M non-cash share-based award vesting.
Restructuring costs expected to be payable over the next several months.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $3.6 million affecting R&D function (reduction-in-force of certain U.S. employees in the Company’s R&D function, including members of its management team).

Type: restructuring
Charge: approximately $3.6 million
Affected area: R&D function
Headcount: reduction-in-force of certain U.S. employees in the Company’s R&D function, including members of its management team

Exact text from the filing

The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $3.6 million, which includes approximately $0.9 million of non-cash expenses related to vesting of share-based awards. These estimates are subject to a number of assumptions, and actual

View on SEC.gov

Browse all restructurings & charges →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-112662

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.